Ropivacaine in oblique subcostal transversus abdominis plane block for laparoscopic sleeve gastrectomy: a randomized, double-blind clinical trial
Acta Cirúrgica Brasileira · 2026 · 41
DOI: 10.1590/acb415826 ↗Abstract
ABSTRACT Purpose: To evaluate the analgesic efficacy, opioid consumption, and inflammatory response of oblique subcostal transversus abdominis plane (OSTAP) block with 0.2% ropivacaine versus control in patients undergoing laparoscopic sleeve gastrectomy (LSG). Methods: This is a prospective, randomized, double-blind, clinical trial. After standardized anesthetic induction, patients received a bilateral OSTAP block with 0.2% ropivacaine or 0.9% saline. Pain, rescue morphine, postoperative nausea and vomiting (PONV), Quality of Recovery-15 (QoR-15), enhanced recovery after bariatric surgery (ERABS) discharge criteria, and inflammatory markers were assessed. Results: Rest pain was similar between groups at all time points. During movement, a lower score was observed at 24 h in the ropivacaine group (RG), median 1 (0–6) versus 2 (0–6), but the difference was not statistically significant after adjustment (p = 0.024; Benjamini-Hochberg [BH] adjusted p = 0.096). Total morphine consumption was similar, 10 (2–50) versus 11 mg (1–30), p = 0.926, as were PONV, QoR-15 118 points, p = 0.717, diet resumption 98, ambulation 76, and ERABS discharge criteria. Interleukin-8 at T3 was numerically lower in the RG, 7.2 (0.6–27.1) versus 9.8 (1.3–18.6) pg/mL, without statistical significance after adjustment (p = 0.073; BH adjusted p = 0.142). Conclusion: OSTAP block with 0.2% ropivacaine was not associated with consistent differences in analgesic, recovery, or inflammatory outcomes.
EUVIMED